In the general population, the prevalence of peanut allergy has remained stable at 1.3%. However, in children, the prevalence appears to be increasing. There are no approved treatments for peanut allergy so current treatment involves educating the patient on avoiding products that contain peanut protein. Two drugs that allow controlled desensitization with controlled amounts of peanut protein have reached late stages of development.
VenterCPereiraBGrundyJet al. Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life. J Allergy Clin Immunol. 2006;117(5):1118-1124.
2.
SichererSHMuñoz-FurlongABurksAWSampsonHA.Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey. J Allergy Clin Immunol. 1999; 103(4):559-562.
3.
SichererSHMuñoz-FurlongASampsonHA.Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol. 2003; 112(6):1203-1207.
4.
SichererSHMuñoz-FurlongAGodboldJHSampsonHA.US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010;125(6):1322-1326.
5.
SkolnickHSConover-WalkerMKKoernerCBSampsonHABurksWWoodRA.The natural history of peanut allergy. J Allergy Clin Immunol. 2001;107(2):367-374.
6.
StiefelGAnagnostouKBoyleRJet al. BSACI guideline for the diagnosis and management of peanut and tree nut allergy. Clin Exp Allergy. 2017;47(6):719-739.
7.
TillesSAPetroniD.FDA-approved peanut allergy treatment: the first wave is about to crest. Ann Allergy Asthma Immunol. 2018;121(2):145-149. doi:10.1016/j.anai.2018.06.005.
BirdJASpergelJMJonesSMet al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476-485.e3. doi:10.1016/j.jaip.2017.09.016.
10.
SampsonHAShrefflerWGYangWHet al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318:1798-1809.
11.
JonesSMSichererSHBurksAWet al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139:1242-1252.
